Skip to main content
Clinical Trials/NCT02195843
NCT02195843UnknownPhase 4

Quadripolar Leads for the Management of Heart Failure Patients in the Middle East

King Abdullah International Medical Research Center0 sites389 target enrollmentStarted: August 1, 2014Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 4
Enrollment
389
Primary Endpoint
Left Ventricular End Systolic Volume (LVESV)

Study Overview

Brief Summary

Heart failure is the most rapidly growing cardiovascular condition in developed countries. Despite advances in medical therapy, patients with heart failure are at high risk for death and hospitalization. Cardiac Resynchronization Therapy - defibrillators (CRT-D) are an effective treatment for heart failure.

Despite the high success rate of a CRT-D implant, there is a possibility of 10% that the LV lead cannot be implanted in patients undergoing a trans-venous system implantation. In this case, the patients may undergo multiple procedures before a lead is successfully implanted. These implant failures are not due to patient selection but rather to patients heart anatomy leading to lead stability problems, phrenic nerve stimulation (also called diaphragmatic stimulation) and poor electrical measurements.

The phrenic nerve is not part of the heart but runs near to this area on the way to a large muscle, called diaphragm, which separates the lung space from the space containing stomach, liver, kidneys and other internal organs in the abdomen. If the lead electrode is close to this nerve, it can cause a small part of it to contract giving you an uncomfortable hiccupping sensation.

In many patients, phrenic nerve stimulation is not identified until after the implant procedure when movement and postural changes bring the LV lead into closer contact with the phrenic nerve.

The investigation is performed to demonstrate the equality of performance of two different modalities of optimization of the implanted device and Quartet lead, Empirical (anatomical) optimization and Right Ventricle Left Ventricle (RVLV) conduction delay optimization.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Male or female patients ≥ 18 years of age
  • •Patient met standard CRT-D device indications (Left Ventricular Ejection Fraction (LVEF) ≤ 35%, QRS ≥ 120 ms, New York Heart Association (NYHA) Class II, III or ambulatory Class IV Heart Failure (HF) symptoms with optimal recommended medical therapy) and will be implanted with an St Jude Medical CRT-D
  • •Patient is willing to provide written informed consent.

Exclusion Criteria

  • •Patient with non left bundle branch block (RBBB, intraventricular delay (IVCD) Block)
  • •Patient has an epicardial ventricular lead system.
  • •Patient has limited intrinsic atrial activity (≤ 40 bpm).
  • •Patient has persistent or permanent Atrial Fibrillation.
  • •Patient's life expectancy is less than 1 year
  • •Patient is pregnant.
  • •Patient is dependent on IV inotropic agents.

Arms & Interventions

Emperical

Active Comparator

Anatomical optimization of device and leads

Intervention: Implanted device and lead (Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system) (Device)

Electrical

Active Comparator

Electrical optimization by RVLV Conduction Time with VectSelect

Intervention: Electrical optimization by RVLV Conduction Time with VectSelect (Other)

Emperical

Active Comparator

Anatomical optimization of device and leads

Intervention: Anatomical optimization of device and leads (Other)

Electrical

Active Comparator

Electrical optimization by RVLV Conduction Time with VectSelect

Intervention: Implanted device and lead (Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system) (Device)

Outcomes

Primary Outcomes

Left Ventricular End Systolic Volume (LVESV)

Time Frame: 6 months post baseline

Positive Clinical response defined as % change of Left Ventricular End Systolic Volume (LVESV) at 6 months follow up, compared to baseline

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Abdulmohsen Al Musa'ad, MD

Consultant Adult Cardiologist

King Abdullah International Medical Research Center

Similar Trials